Drugs in Development for Acute Kidney Injury
Drugs in Development for Acute Kidney Injury
复制标题
DOI：
10.1007/s40265-019-01119-8
复制
发表时间：
2019-06-01
期刊：
影响因子：
11.5
通讯作者：
Rosner, Mitchell H.
中科院分区：
文献类型：
--
作者：
Hulse, Matthew;Rosner, Mitchell H.
急性肾损伤(AKI)患者的治疗一直受到限制，因为缺乏有效的治疗方法，既可以在高危情况下预防AKI，也可以在AKI确诊后进行治疗。对AKI发病机制的科学认识上的一场革命导致了潜在治疗靶点的确定。这些靶点包括参与炎症、细胞修复和纤维化、细胞代谢和线粒体功能、氧化应激、细胞凋亡以及血流动力学和氧气输送的途径。许多化合物正在进入早期临床试验。此外，更好地描述AKI亚类的努力(通过内标表型)有望根据在发病机制中起作用的途径更有效地进行靶向治疗。这些进展带来了乐观情绪，即AKI患者的护理将因希望更好的结果而改变。
The care of patients with acute kidney injury (AKI) has been limited due to the lack of effective therapeutics that can either prevent AKI during high-risk situations or treat AKI once established. A revolution in the scientific understanding of the pathogenesis of AKI has led to the identification of potential therapeutic targets. These targets include pathways involved in inflammation, cellular repair and fibrosis, cellular metabolism and mitochondrial function, oxidative stress, apoptosis, and hemodynamics and oxygen delivery. Many compounds are entering early-phase clinical trials. In addition, efforts to better describe sub-categories of AKI (through endo-phenotyping) hold promise to target therapies more effectively based upon pathways that are operative in the pathogenesis. These advances bring optimism that the care of patients with AKI will be transformed with the hope of better outcomes.